TSCAN THERAPEUTICS, INC. Operating Lease Cost
TSCAN THERAPEUTICS, INC. (TCRX) reported Operating Lease Cost of $13.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-04
- TSCAN THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $13.00M, a 12.39% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $11.56M, a 8.83% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $10.63M, a 225.55% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $3.26M, a 68.33% increase from fiscal 2021.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $13.00M 10-K · filed 2026-03-04 |
| 2024-12-31 | $11.56M 10-K · filed 2026-03-04 |
| 2023-12-31 | $10.63M 10-K · filed 2025-03-05 |
| 2022-12-31 | $3.26M 10-K · filed 2024-03-06 |
| 2021-12-31 | $1.94M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |